Project description
Immunotherapy for a rare adolescence cancer
Chimeric antigen receptor T-cell (CAR-T) therapy is a revolutionary form of immunotherapy that involves the genetic modification of a patient's own T-cells to target and destroy cancer cells. It has shown remarkable success in treating certain types of cancer, particularly blood cancers like leukemia and lymphoma. The EU-funded DSRCT-CAR project aims to develop CAR-T therapy against desmoplastic small round cell tumour (DSRCT), a rare and aggressive sarcoma that mainly affects adolescents and young adults. Researchers aim to address the limited success of chemotherapy and surgery in the treatment of DSRCT and improve the clinical outcome of patients.
Objective
Desmoplastic small round cell tumor (DSRCT) is an aggressive rare sarcoma that occurs in adolescents and young adults. DSRCT has a dismal prognosis: despite aggressive therapy, 3-year overall survival has been estimated at 44% and the 5-year survival rate remains around 15%. Current therapeutic approaches, including chemotherapy (remain highly toxic) and surgery, are yet to achieve complete disease control. The development of safe and efficient molecularly targeted-therapies, as well as a comprehensive understanding of the molecular driver of the disease, are highly needed to ultimately improve patient outcome.
The originality of this proposal relies on intersecting complementary scientific areas, as the high level of maturity I have acquired both on the molecular basis of DSRCT and on the corresponding cellular and animal models, and a novel form of immunotherapy, as CAR-T cells (which the host group is actively working on), for the treatment of DSRCT. It will be carried out under the guidance of Prof. Moreira from CNC/UC, who holds more than 25 years of experience in the field of targeted delivery to solid tumors and successful entrepreneur.
This Fellowship, in line with Europe Mission on Cancer, is a life time opportunity that will enable me to become a highly qualified researcher, with differentiated background (combining – existing - molecular cancer pharmacology with targeting strategies to solid tumors) and novel transferable skills, among the post-doc universe entering the job market. It will enable me to generate and integrate interdisciplinary knowledge with added economic value, with know-how on how to translate it towards the market and the patients. Overall, these are relevant features to support the sustainability of any organization. As such, approval of this Marie Sklodowska-Curie European Fellowship will give me a wide avenue of opportunities to further pursue a career either in Academia or Pharmaceutical Industry.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences clinical medicine surgery
- social sciences economics and business business and management entrepreneurship
- medical and health sciences clinical medicine oncology
- medical and health sciences basic medicine immunology immunotherapy
- medical and health sciences basic medicine pharmacology and pharmacy
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
HORIZON.4.1 - Widening participation and spreading excellence
MAIN PROGRAMME
See all projects funded under this programme -
HORIZON.4.1.5 - Fostering brain circulation of researchers and excellence initiatives
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) HORIZON-WIDERA-2022-TALENTS-04
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
3004-531 COIMBRA
Portugal
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.